Córdoba QM

Language: Spanish
References: 32
Page: 811-816
PDF size: 772.36 Kb.

ABSTRACT

Dry eye syndrome is a disease of which little was known; however in recent years has gone into its pathogenesis. Currently, although the same lack of understanding, it is known that is a multifactorial disease of the eye and ocular surface. Thanks to new discoveries in its genesis, efforts have been concentrated towards getting an effective treatment.

REFERENCES

1. Abelson M.B., G.W. Ousler III, L.A. Nally, D. Welch, and K. Krenzer, “Alternative reference values for tear film break up time in normal and dry eye populations,” Advances in Experimental Medicine and Biology, vol. 506, pp. 1121–1125, 2002.

2. Aditya Rege, Varsha Kulkarni, Neelam Puthran, Tejaswini Khandgave. A Clinical Study of Subtype-based Prevalence of Dry Eye. Journal of Clinical and Diagnostic Research. 2013 Oct, Vol- 7(10): 2207-2210.

3. American Academy of Ophtalmology. External Disease and Cornea, Section 8. 2011-2012. Chapter 3 Ocular Surface Disease: Diagnostic Approach. 48-75.

4. American Academy of Ophtalmology Fundamentals and Principles of Ophtalmology, Section 2. 2011-2012. Part IV Biochemistry and Metabolism. Chapter 7 Tear Film. 237-246.

5. Buchholz P.,C.S.Steeds,L.S.Sterneta l.,“Utility assessment to measure the impact of dry eye disease,” Ocular Surface, vol. 4, no. 3, pp. 155–161, 2006.

6. Creuzot-Garcher C, Lafontaine PO, Brignole F, et al. [Treating severe dry eye syndromes with autologous serum]. J Fr Ophthalmol. 2004;27:346–51.

7. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporine A in the treatment of anterior segment inflammatory disease. Cornea. 1993;12:413–9.

8. Hong S, Kim T, Chung SH, et al. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren’s syndrome. J Ocul Pharmacol Ther. 2007;23:78–82.

9. Hülya Devecı et al, The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren’s síndrome Int Ophthalmol DOI 10.1007/ s10792-014-9901-4.

10. Jackson W.B., “Management of dysfunctional tear syndrome: a Canadian consensus,” Canadian Journal of Ophthalmology, vol. 44, no. 4, pp. 385–394, 2009.

11. Karampatakis V., A. Karamitsos, A. Skriapa, and G. Pastiadis, “Comparison between normal values of 2- and 5-minute schirmer test without anesthesia,” Cornea, vol. 29, no. 5, pp. 497– 501, 2010.

12. Katy C. Liu et al, Autoimmunity in the Pathogenesis and Treatment of Keratoconjunctivitis Sicca. Curr Allergy Asthma Rep (2014) 14:403.

13. Kim KW, HanS B,Han ER, et al. Association between depression and dry eye disease in an elderly population. Invest Ophthalmol Vis Sci. 2011;52(11):7954-7958.

14. Koray Gumus et al, The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca. Clinical Ophthalmology 2009:3 57–67.

15. Lee AJ, Lee J, Saw SM, Gazzard G, Koh D, Widjaja D, et al. Prevalence and Risk Factors Associated With Dry Eye Symptoms: A Populationbased Study in Indonesia. Br J Ophthalmol. 2002; 86:1347-51.

16. Mohammad-Ali Javadi, Sepehr Feizi. Dry Eye Syndrome. J Ophthalmic Vis Res 2011; 6 (3): 192-198.

17. Moss S.E., R. Klein, and B. E. K. Klein, “Prevalance of and risk factors for dry eye syndrome,” Archives of Ophthalmology, vol. 118, no. 9, pp. 1264–1268, 2000.

18. Oleñik Andrea, Effectiveness and tolerability of dietary supplementation with a combination of omega-3 polyunsaturated fatty acids and antioxidants in the treatment of dry eye symptoms: results of a prospective study. Clinical Ophthalmology 2014:8 169–176.

19. Qihua Le et al. Comparison on the vision-related quality of life between outpatients and general population with dry eye síndrome. 2013 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. doi: 10.1111/ aos.12204.

20. Rahman A, Yahya K, Validity of Symptoms as Screening Toll for Dry Eye. Pak J Ophthalm. 2007; 23(4): 198-203.

21. Sahin A, Bozkurt B, Irkec M. Topical cyclosporine A in the treatment of superior limbic keratoconjunctivitis: a long-term follow-up. Cornea. 2008;27:193–5.

22. Schein OD, Muñoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723-728.

23. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and Validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000; 118:615-21.

24. Sheppard John D. et al, Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to- Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial. Cornea 2013;32:1297–1304.

25. Snjezana Kaštelan et al. Diagnostic Procedures and Management of Dry Eye. Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 309723, 6 pages.

26. Stevenson William et al. Dry Eye Disease An Immune-Mediated Ocular Surface Disorder. Arch Ophthalmol. 2012;130(1):90-100.

27. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007; 5(2):75-92.

28. Trinka Vijmasi et al, Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoinmune disease. Molecular Vision 2013; 19:1957-1965.

29. Tsubota K, Fujita H, Tadano K, Takeuchi T, Murakami T, Saito I, et al. Improvement of lacrimal function by topical application of CyA in murine models of Sjogren’s syndrome. Investig Ophthalmol Vis Sci. 2001;42(1):101–10.

30. Vehof et al, Relationship Between Dry Eye Symptoms and Pain Sensitivity, AMA Ophthalmol.2013;131(10):1304-308. doi:1.1001/jamaophthalmol. 2013. 4399

31. Yokoi N., A. J. Bron, J. M. Tiffany, K. Maruyama, A. Komuro, and S. Kinoshita, “Relationship between tear volume and tear meniscus curvature,” Archives of Ophthalmology, vol. 122, no. 9, pp. 1265–1269, 2004.

32. Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol. 2007;144:86–92.